Gulf Coast Scientific, a 25-year leader in non-invasive diagnostic testing and the maker of the FDA-approved, market-leading urea breath test for H. pylori, sought a strategic partner to expand awareness, accelerate global growth, and support its pipeline of pulmonary-based diagnostic tests.

Carl Marks Securities advised the Gulf Coast family through a comprehensive sale process, identifying SSI Diagnostica Group, a global infectious-disease diagnostics leader with complementary gastric, respiratory, and blood-borne testing platforms, as the optimal acquirer.

Gulf Coast was successfully sold to SSI Diagnostica Group, with leadership joining SSID’s management team. The combination enhances global reach, strengthens the companies’ H. pylori diagnostic offerings, and positions the platform for continued innovation and international expansion.